161 related articles for article (PubMed ID: 28106035)
1. Esterase mutation is a mechanism of resistance to antimalarial compounds.
Istvan ES; Mallari JP; Corey VC; Dharia NV; Marshall GR; Winzeler EA; Goldberg DE
Nat Commun; 2017 Jan; 8():14240. PubMed ID: 28106035
[TBL] [Abstract][Full Text] [Related]
2. Plasmodium falciparum Resistance to a Lead Benzoxaborole Due to Blocked Compound Activation and Altered Ubiquitination or Sumoylation.
Sindhe KMV; Wu W; Legac J; Zhang YK; Easom EE; Cooper RA; Plattner JJ; Freund YR; DeRisi JL; Rosenthal PJ
mBio; 2020 Jan; 11(1):. PubMed ID: 31992618
[TBL] [Abstract][Full Text] [Related]
3. Antimalarial effects of human immunodeficiency virus type 1 protease inhibitors differ from those of the aspartic protease inhibitor pepstatin.
Parikh S; Liu J; Sijwali P; Gut J; Goldberg DE; Rosenthal PJ
Antimicrob Agents Chemother; 2006 Jun; 50(6):2207-9. PubMed ID: 16723585
[TBL] [Abstract][Full Text] [Related]
4. Resistance to Some But Not Other Dimeric Lindenane Sesquiterpenoid Esters Is Mediated by Mutations in a
Butler JH; Baptista RP; Valenciano AL; Zhou B; Kissinger JC; Tumwebaze PK; Rosenthal PJ; Cooper RA; Yue JM; Cassera MB
ACS Infect Dis; 2020 Nov; 6(11):2994-3003. PubMed ID: 32970404
[TBL] [Abstract][Full Text] [Related]
5. 3-Halo Chloroquine Derivatives Overcome Plasmodium falciparum Chloroquine Resistance Transporter-Mediated Drug Resistance in P. falciparum.
Edaye S; Tazoo D; Bohle DS; Georges E
Antimicrob Agents Chemother; 2015 Dec; 59(12):7891-3. PubMed ID: 26438496
[TBL] [Abstract][Full Text] [Related]
6. Plasmodium falciparum: differential sensitivity in vitro to E-64 (cysteine protease inhibitor) and Pepstatin A (aspartyl protease inhibitor).
Bailly E; Jambou R; Savel J; Jaureguiberry G
J Protozool; 1992; 39(5):593-9. PubMed ID: 1522541
[TBL] [Abstract][Full Text] [Related]
7. Plasmodium falciparum Cyclic Amine Resistance Locus (PfCARL), a Resistance Mechanism for Two Distinct Compound Classes.
Magistrado PA; Corey VC; Lukens AK; LaMonte G; Sasaki E; Meister S; Wree M; Winzeler E; Wirth DF
ACS Infect Dis; 2016 Nov; 2(11):816-826. PubMed ID: 27933786
[TBL] [Abstract][Full Text] [Related]
8. Double-drug development against antioxidant enzymes from Plasmodium falciparum.
Biot C; Dessolin J; Grellier P; Davioud-Charvet E
Redox Rep; 2003; 8(5):280-3. PubMed ID: 14962365
[TBL] [Abstract][Full Text] [Related]
9. A Redox-Active Fluorescent pH Indicator for Detecting Plasmodium falciparum Strains with Reduced Responsiveness to Quinoline Antimalarial Drugs.
Jida M; Sanchez CP; Urgin K; Ehrhardt K; Mounien S; Geyer A; Elhabiri M; Lanzer M; Davioud-Charvet E
ACS Infect Dis; 2017 Feb; 3(2):119-131. PubMed ID: 28183182
[TBL] [Abstract][Full Text] [Related]
10. KBE009: An antimalarial bestatin-like inhibitor of the Plasmodium falciparum M1 aminopeptidase discovered in an Ugi multicomponent reaction-derived peptidomimetic library.
González-Bacerio J; Maluf SEC; Méndez Y; Pascual I; Florent I; Melo PMS; Budu A; Ferreira JC; Moreno E; Carmona AK; Rivera DG; Alonso Del Rivero M; Gazarini ML
Bioorg Med Chem; 2017 Sep; 25(17):4628-4636. PubMed ID: 28728898
[TBL] [Abstract][Full Text] [Related]
11. Nucleotide analogues containing a pyrrolidine, piperidine or piperazine ring: Synthesis and evaluation of inhibition of plasmodial and human 6-oxopurine phosphoribosyltransferases and in vitro antimalarial activity.
Frydrych J; Keough DT; Chavchich M; Travis J; Dračínský M; Edstein MD; Guddat LW; Hocková D; Janeba Z
Eur J Med Chem; 2021 Jul; 219():113416. PubMed ID: 33887682
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of Plasmodium falciparum mutations associated with antimalarial drug resistance during an epidemic in Kuna Yala, Panama, Central America.
Samudio F; Santamaría AM; Obaldía N; Pascale JM; Bayard V; Calzada JE
Am J Trop Med Hyg; 2005 Nov; 73(5):839-41. PubMed ID: 16282290
[TBL] [Abstract][Full Text] [Related]
13. Prodomain processing of recombinant plasmepsin II and IV, the aspartic proteases of Plasmodium falciparum, is auto- and trans-catalytic.
Kim YM; Lee MH; Piao TG; Lee JW; Kim JH; Lee S; Choi KM; Jiang JH; Kim TU; Park H
J Biochem; 2006 Feb; 139(2):189-95. PubMed ID: 16452306
[TBL] [Abstract][Full Text] [Related]
14. Covalent Plasmodium falciparum-selective proteasome inhibitors exhibit a low propensity for generating resistance in vitro and synergize with multiple antimalarial agents.
Stokes BH; Yoo E; Murithi JM; Luth MR; Afanasyev P; da Fonseca PCA; Winzeler EA; Ng CL; Bogyo M; Fidock DA
PLoS Pathog; 2019 Jun; 15(6):e1007722. PubMed ID: 31170268
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the autophagy marker protein Atg8 reveals atypical features of autophagy in Plasmodium falciparum.
Navale R; Atul ; Allanki AD; Sijwali PS
PLoS One; 2014; 9(11):e113220. PubMed ID: 25426852
[TBL] [Abstract][Full Text] [Related]
16. Antimalarial activity of HIV-1 protease inhibitor in chromone series.
Lerdsirisuk P; Maicheen C; Ungwitayatorn J
Bioorg Chem; 2014 Dec; 57():142-147. PubMed ID: 25462990
[TBL] [Abstract][Full Text] [Related]
17. Substrate-analogous inhibitors exert antimalarial action by targeting the Plasmodium lactate transporter PfFNT at nanomolar scale.
Golldack A; Henke B; Bergmann B; Wiechert M; Erler H; Blancke Soares A; Spielmann T; Beitz E
PLoS Pathog; 2017 Feb; 13(2):e1006172. PubMed ID: 28178358
[TBL] [Abstract][Full Text] [Related]
18. In vitro mutagenesis defines drug targets in aldolase of Plasmodium falciparum.
Certa U; Itin C; Döbeli H
Mem Inst Oswaldo Cruz; 1992; 87 Suppl 3():263-4. PubMed ID: 1343698
[No Abstract] [Full Text] [Related]
19. Resistance mutations at the lipid substrate binding site of Plasmodium falciparum protein farnesyltransferase.
Eastman RT; White J; Hucke O; Yokoyama K; Verlinde CL; Hast MA; Beese LS; Gelb MH; Rathod PK; Van Voorhis WC
Mol Biochem Parasitol; 2007 Mar; 152(1):66-71. PubMed ID: 17208314
[TBL] [Abstract][Full Text] [Related]
20. Targeting the Plasmodium vivax equilibrative nucleoside transporter 1 (PvENT1) for antimalarial drug development.
Deniskin R; Frame IJ; Sosa Y; Akabas MH
Int J Parasitol Drugs Drug Resist; 2016 Apr; 6(1):1-11. PubMed ID: 26862473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
